ADCS/NIA PROTOCOL ACD-016: HIGH DOSE SUPPLEMENTS AND ALZHEIMER'S DISEASE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。血液中同型半胱氨酸是一种硫磺氨基酸，已被证明在阿尔茨海默病(AD)患者中水平升高。高同型半胱氨酸血症可能通过血管和直接神经毒性机制参与疾病的病理生理过程。同型半胱氨酸水平可以通过大剂量补充叶酸和维生素B6和B12来降低。FDA已经批准了四种药物用于治疗AD，这些都是胆碱酯酶抑制剂。通过提高大脑神经递质乙酰胆碱的水平，它们改善了认知功能。它们被认为是对症治疗；它们还没有被证明可以减缓疾病的发展。这一建议是基于同型半胱氨酸减少将在AD中起到疾病改善作用的假设的。这项试验是一项为期18个月的随机试验，共有40个地点的400名患者参加。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Blood levels of homocysteine, a sulfur amino acid, have been demonstrated to be elevated in Alzheimer's Disease (AD). Hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Homocysteine levels can be reduced by administration of high dose supplements of folic acid and vitamins B6 and B12. Four drugs have been approved by the FDA for the treatment of AD, all cholinesterase inhibitors. By boosting brain levels of the neurotransmitter acetylcholine, they improve cognitive function. They are considered to be symptomatic treatments; they have not been proven to slow the progression of the disease. This proposal is based on the hypothesis that homocysteine reduction will have a disease-modifying effect in AD. This trial is an eighteen month randomized trial of 400 patients at 40 sites.